



CYTOGENETICS 101 eSEMINARS

Ready to learn about using microarrays for genetic or pre-implantation research?



BioArray News

The Global Weekly of Biochips & Microarrays

Welcome who. Log out. | My account

Home News Blogs Careers Webinars White Papers

SEARCH

Se

Arrays Clinical Genomics Informatics PCR Proteomics RNAi/miRNA Sequencing

Wednesday, April 23, 2014

Applied BioCode Developing Multiplex, Bead-Based Gastrointestinal Pathogen Detection Panel

April 22, 2014

By Justin Petrone

Type size: | |

Email

Printer-friendly version

RSS Feed

NEW YORK (GenomeWeb) — Applied BioCode is developing a new test for gastrointestinal pathogens that it hopes to sell to high-volume hospital laboratories and that will compete directly with Luminex's US Food and Drug Administration-cleared Gastrointestinal Pathogen Panel.

The Santa Fe Springs, Calif.-based company is also working on a high-throughput, 96-well platform to support the assay, according to company executives.

Applied BioCode CEO Winston Ho and Bob Wessel, a marketing and business development consultant for the firm, discussed the new test and platform with *BioArray News* this week. They also provided a poster about the assay that the firm intends to present at the upcoming Annual Clinical Virology Symposium, which will be held later this month in Daytona Beach, Fla.

Applied BioCode's panel contains 16 targets associated with gastroenteritis, including 10 bacteria, three viruses, and three parasites. The panel is run using the company's barcoded magnetic beads technology, where targets are coupled to barcoded beads, providing a high-contrast transmitted signal, no fluorescence background, and nearly 100 percent decoding accuracy, according to the firm.

Though the company sells two analyzers for decoding its beads, it is developing a 96-well format, high-throughput system to support the new panel, which, if cleared by the FDA, will be its first *in vitro* diagnostic.

"Molecular diagnostics is a rapidly growing area and a GI panel is an offering where we feel we can add value with our technology," said Wessel.

He noted that the company has decided to focus on high-throughput labs, which will differentiate it from assays and systems sold by Nanosphere, bioMérieux's BioFire Diagnostics, and other firms that offer cartridge-based tests. And in addition to making it possible to analyze up to 96 samples at a time, the firm is also looking to integrate thermocycling, hybridization, and detection processes within one system, attributes that could distinguish it from Luminex's Gastrointestinal Pathogen Panel.

In this issue of BioArray News

- Affymetrix, CollabRx Deal Adds Copy Number Interpretation to Clinical Research Labs' Analytical Workflows
- **Applied BioCode Developing Multiplex, Bead-Based Gastrointestinal Pathogen Detection Panel**
- New CMA Study Finds Capability to Detect CNVs Has 'Outpaced' Ability to Deduce Their Role in Disease
- In Print: Last Week's Microarray Papers of Note


Gradient PCR. Touchscreen. **\$2495.**

LifeECO
Gradient Thermal Cycler
NEWEST MODEL!

96-well capacity
What more could you ask for?

This meeting is nearly sold out

The 2nd
Plant Genomics Congress
12 - 13 May 2014
London, UK



- GenomeWebinars
- Young Investigator Profile
- Blog

High Promise

Technology Review includes genome editing on its list of 'breakthrough technologies.'

Bacterial Bills

Through genetic analysis, researchers find a bevy of bacteria on your dollar bills.

Barriers and Promise

Elaine Mardis discusses the translation of cancer genomics findings to clinical care and more.

This Week in Genome Biology

In *Genome Biology* this week: DNA methylation patterns of various human tissues, stomach cancer sequencing, and more.

- Papers of Note
- People on the Move

Big Data in Pharma

Manage and analyse big data to enhance R&D and clinical trials for the future!

12th - 13th
MAY 2014

Holiday Inn Regents Park Hotel, London, UK



Genome Technology Magazine Archive

- Genome Technology Digital Editions Archive
- Tech Guide Archives

According to Wessel, it is Applied BioCode's goal to deliver a system to market that is has a number of advantages over other offerings in the market.

"The main issue for us is providing a system that is more user friendly and suffers less from sample contamination," Wessel said. It will also benefit from the firm's technology platform, he maintained, as each bead will have its own barcode, making it "easier to differentiate the targets" via direct microplate imaging.

Ho, the CEO, characterized Applied BioCode's technology is a "digital multiplex bead platform" that is "very reproducible and very stable," noting that the semiconductor process the firm uses to produce its beads results in "no variation" between assays. Ho also said that it is possible that the company's new 96-well system could be available for research in the future, though he declined to elaborate

FDA clearance will be paramount for the launch of Applied BioCode's new test. The agency [cleared Luminex's GPP](#) for use on its high-throughput LX 200 system in January 2013 and again for use on its MagPix benchtop instrument last April. The test is based on Luminex's bead array technology and enables users to detect 11 gastrointestinal pathogens in a single, five-hour assay. The company has predicted that its GPP will be a "key growth driver" this year.

Wessel said that Applied BioCode hopes to be able to submit its assay to the FDA for review early next year.

In terms of challenging Luminex in the global market place, Wessel said that Applied BioCode will price the system competitively, and will work with distribution partners to make it available worldwide.

Applied BioCode also has some partners who are developing somewhat related tests. Oslo, Norway-based Genetic Analysis [announced earlier this year](#) that it had achieved a CE IVD marking for its GA-map IBS Dysbiosis test, which targets dysbiosis — an imbalance of gut microbacteria that can lead to the development of irritable bowel disease and other gastrointestinal ailments is now CE marked and available for use on clinical samples in European labs. The company also announced at the time that it had signed a license and supply agreement with Applied BioCode for its barcoded magnetic bead technology for multiplex array analysis.

Wessel acknowledged Applied BioCode's relationship with Genetic Analysis, but noted that its internal GI assay differs from its partner's assay in terms of indication and platform.



Justin Petrone is the editor of GenomeWeb's *BioArray News* and covers the microarray and biochip sector of the genomics market. E-mail [Justin Petrone](mailto:Justin.Petrone@genomeweb.com) or follow his GenomeWeb Twitter account at [@BioArrayNews](https://twitter.com/BioArrayNews).

Related Stories

[Luminex Predicts Gastrointestinal Pathogen Panel will be 'Key Growth Driver' in 2014](#)
February 11, 2014 / BioArray News

[Reimbursement Issues, NMTC Bankruptcy among Luminex's Challenges in Q3](#)
November 5, 2013 / BioArray News

[DTC Developments, Luminex Dx Plans, Biobank Deals Topped Readers' Interests in 2013](#)

Upcoming Events

REVOLUTIONIZING
BEGINS WITH
CUSTOMIZING.

Learn More 

 Agilent Technologies

Polls

How do you think changes to the NIH grant submission policy will affect the funding process?

- The number of grants to review will explode.
- I'll be spending more time trying to get a grant.
- An even smaller percentage of applications will be funded.
- This should strengthen applications that are submitted.
- I won't have to spend as much time tweaking my applications.
- Reviewers will still notice when the same application comes through again and again.
- I'm not sure. We'll see soon enough.

[View Results](#)